BiomX appoints Eddie Williams as Class I Director to fill board vacancy

BiomX Inc.

Eddie Williams appointed Class I Director, term expires at 2024 annual meeting.
Williams is independent under NYSE American rules and entered indemnification agreement.
He currently serves on BioAtla (BCAB) board; previously Catalyst Biosciences (CBIO) board.
Previously SVP at Novo Nordisk and VP at Novartis; over 20 years pharma experience.
Appointment effective October 12, 2023; no arrangement with any other person.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eddie Williams

Class I Director

PHGE · BiomX Inc.

Effective: 2023-10-12
Filed: October 18, 2023, 7:59 PM ET

On October 12, 2023, the Board of Directors (the “Board”) of BiomX Inc. (the “Company”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Eddie Williams to serve as Class I Director of the Company, with a term expiring at the Company’s 2024 annual meeting of stockholders, in order to fill an existing vacancy on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eddie Williams was appointed as Class I Director at BiomX Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On October 12, 2023, the Board of Directors (the “Board”) of BiomX Inc. (the “Company”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Eddie Williams to serve as Class I Director of the Company, with a term expiring at the Company’s 2024 annual meeting of stockholders, in order to fill an existing vacancy on the Board.

View on SEC.gov

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001013762-23-004638

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.